UK markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.5710+0.1053 (+22.61%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4657
Open0.6128
BidN/A x N/A
AskN/A x N/A
Day's range0.4485 - 0.6128
52-week range0.0600 - 0.9700
Volume394,827
Avg. volume40,846
Market cap189.035M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.1610
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

    Lead candidate SPL026 granted MHRA Innovation Passport DesignationLONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from

  • Globe Newswire

    Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

    Enables Access for U.S. Investors to Support Small Pharma’s Vision to Broaden the Mental Health Treatment LandscapeLONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its successful upgrade from the OTC Pink to the OTCQB® Venture Market (the “OTCQB”), a United States trading platform that is operated by the OTC Markets Group Inc. in

  • Globe Newswire

    First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

    Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder Program remains on track for topline results in H1 2022 LONDON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that the first patient has been dosed in the Company’s Phase IIa clinical trial for its lead N,N-dimethyltrypta